Serum miR-181b Is Correlated with Hepatitis B Virus Replication and Disease Progression in Chronic Hepatitis B Patients

Digestive Diseases and Sciences

Volumn 60, Issue 8, 2015, Pages 2346-2352

  Yu, Fujun ^a   Zhou, Guangyao ^b   Li, Guojun ^c   Chen, Bicheng ^a   Dong, Peihong ^a   Zheng, Jianjian ^a  

^a THE FIRST AFFILIATED HOSPITAL OF WENZHOU MEDICAL UNIVERSITY   (China)

^b THE SECOND AFFILIATED HOSPITAL AND YUYING CHILDREN S HOSPITAL OF WENZHOU MEDICAL UNIVERSITY   (China)

^c Ningbo Second People Hospital   (China)

Author keywords

Biomarker; Chronic hepatitis B; Liver fibrosis; Serum microRNA 181b

Indexed keywords

ALANINE AMINOTRANSFERASE; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; MICRORNA; MICRORNA 181B; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; MIRN181 MICRORNA, HUMAN; VIRUS DNA;

ADULT; ARTICLE; CHRONIC HEPATITIS B; CONTROLLED STUDY; DISEASE COURSE; FEMALE; GENE EXPRESSION; GENETIC ASSOCIATION; HUMAN; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; VIRUS REPLICATION; BLOOD; HEPATITIS B; HEPATITIS B VIRUS; MIDDLE AGED; PHYSIOLOGY; VIROLOGY;

ADULT; BIOLOGICAL MARKERS; DNA, VIRAL; FEMALE; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; MALE; MICRORNAS; MIDDLE AGED; VIRUS REPLICATION;

EID: 84937521378     PISSN: 01632116     EISSN: 15732568     Source Type: Journal    
DOI: 10.1007/s10620-015-3649-1     Document Type: Article

References (35)

1. Dienstag JL. Hepatitis B virus infection. N Engl J Med. 2008;359:1486–1500.
2. McMahon BJ Epidemiology and natural history of hepatitis B. Seminars in Liver Disease. 2005;25:3–8.
3. Chen CJ, Yang HI, Su J, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. J Am Med Assoc. 2006;295:65–73.
4. Liu X, Wan X, Li Z, Lin C, Zhan Y, Lu X. Golgi protein 73(GP73), a useful serum marker in liver diseases. Clin Chem Lab Med CCLM/FESCC. 2011;49:1311–1316.
5. Li L, Guo Z, Wang J, Mao Y. Gao Q Serum miR-18a: a potential marker for hepatitis B virus-related hepatocellular carcinoma screening. Dig Dis Sci. 2012;57:2910–2916.
6. Degertekin B. Lok AS Indications for therapy in hepatitis B. Hepatology. 2009;49:S129–S137.
7. Bartel DP. MicroRNAs genomics, biogenesis, mechanism, and function. Cell. 2004;116:281–297.
8. Croce CM, Calin GA. miRNAs, cancer, and stem cell division. Cell. 2005;122:6–7.
9. Esquela-Kerscher A, Slack FJ. Oncomirs—microRNAs with a role in cancer. Nat Rev Cancer. 2006;6:259–269.
10. Kloosterman WP, Plasterk RH. The diverse functions of microRNAs in animal development and disease. Dev Cell. 2006;11:441–450.
11. Wang B, Li W, Guo K, Xiao Y, Wang Y, Fan J. miR-181b promotes hepatic stellate cells proliferation by targeting p27 and is elevated in the serum of cirrhosis patients. Biochem Biophys Res Commun. 2012;421:4–8.
12. Chen X, Ba Y, Ma L, et al. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res. 2008;18:997–1006.
13. Fang C, Zhu DX, Dong HJ, et al. Serum microRNAs are promising novel biomarkers for diffuse large B cell lymphoma. Ann Hematol. 2012;91:553–559.
14. Gilad S, Meiri E, Yogev Y, et al. Serum microRNAs are promising novel biomarkers. PLoS ONE. 2008;3:e3148.
15. Mitchell PS, Parkin RK, Kroh EM, et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci USA. 2008;105:10513–10518.
16. Bihrer V, Friedrich-Rust M, Kronenberger B, et al. Serum miR-122 as a biomarker of necroinflammation in patients with chronic hepatitis C virus infection. Am J Gastroenterol. 2011;106:1663–1669.
17. Qi P, Cheng SQ, Wang H, Li N, Chen YF, Gao CF. Serum microRNAs as biomarkers for hepatocellular carcinoma in Chinese patients with chronic hepatitis B virus infection. PLoS ONE. 2011;6:e28486.
18. Xu J, Wu C, Che X, et al. Circulating microRNAs, miR-21, miR-122, and miR-223, in patients with hepatocellular carcinoma or chronic hepatitis. Mol Carcinog. 2011;50:136–142.
19. Zheng J, Wu C, Xu Z, et al. Hepatic stellate cell is activated by microRNA-181b via PTEN/Akt pathway. Mol Cell Biochem. 2015;398:1–9.
20. Huang C, Zheng JM, Cheng Q, et al. Serum microRNA-29 levels correlate with disease progression in patients with chronic hepatitis B virus infection. J Dig Dis. 2014;15:614–621.
21. 2004 guidelines for surgical treatment of primary hepatocellular carcinoma. Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese J Hepatol. 2005;13:329–330.
22. Ishak K, Baptista A, Bianchi L, et al. Histological grading and staging of chronic hepatitis. J Hepatol. 1995;22:696–699.
23. Yao J, Liang L, Huang S, et al. MicroRNA-30d promotes tumor invasion and metastasis by targeting Galphai2 in hepatocellular carcinoma. Hepatology. 2010;51:846–856.
24. Coppola N, Potenza N, Pisaturo M, et al. Liver microRNA hsa-miR-125a-5p in HBV chronic infection: correlation with HBV replication and disease progression. PLoS ONE. 2013;8:e65336.
25. Ozer J, Ratner M, Shaw M, Bailey W, Schomaker S. The current state of serum biomarkers of hepatotoxicity. Toxicology. 2008;245:194–205.
26. Amacher DE, Adler R, Herath A, Townsend RR. Use of proteomic methods to identify serum biomarkers associated with rat liver toxicity or hypertrophy. Clin Chem. 2005;51:1796–1803.
27. Ebert MP, Korc M, Malfertheiner P, Rocken C. Advances, challenges, and limitations in serum-proteome-based cancer diagnosis. J Proteome Res. 2006;5:19–25.
28. Zhang Y, Jia Y, Zheng R, et al. Plasma microRNA-122 as a biomarker for viral-, alcohol-, and chemical-related hepatic diseases. Clin Chem. 2010;56:1830–1838.
29. Russo A, Potenza N. Antiviral effects of human microRNAs and conservation of their target sites. FEBS Lett. 2011;585:2551–2555.
30. Park SO, Kumar M, Gupta S. TGF-beta and iron differently alter HBV replication in human hepatocytes through TGF-beta/BMP signaling and cellular microRNA expression. PLoS ONE. 2012;7:e39276.
31. Potenza N, Papa U, Mosca N, Zerbini F, Nobile V, Russo A. Human microRNA hsa-miR-125a-5p interferes with expression of hepatitis B virus surface antigen. Nucleic Acids Res. 2011;39:5157–5163.
32. Zhang GL, Li YX, Zheng SQ, Liu M, Li X, Tang H. Suppression of hepatitis B virus replication by microRNA-199a-3p and microRNA-210. Antiviral Res. 2010;88:169–175.
33. Liu Y, Zhao JJ, Wang CM, et al. Altered expression profiles of microRNAs in a stable hepatitis B virus-expressing cell line. Chin Med J. 2009;122:10–14.
34. Waidmann O, Bihrer V, Pleli T, et al. Serum microRNA-122 levels in different groups of patients with chronic hepatitis B virus infection. J Viral Hepatitis. 2012;19:e58–e65.
35. Iloeje UH, Yang HI, Su J, Jen CL, You SL, Chen CJ. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology. 2006;130:678–686.